Methods and materials for treating t cell disorders
Patent Information
- Application Number
- PCT/US2026/020340
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-03-31
- Filing Date
- 2026-03-23
- Publication Date
- 2026-11-12
AI Technical Summary
Current treatments for T cell disorders, such as T cell cancers, autoimmune diseases, and transplant rejection, lack specificity and efficacy in targeting T cell receptor beta chain constant region 1 (TRBC1) polypeptides, leading to poor prognosis and ineffective therapies.
Development of binding agents, including single-chain variable fragments (scFvs) and antibodies, that specifically target TRBC1 polypeptides with minimal binding to TRBC2, allowing for targeted treatment of T cell cancers, autoimmune diseases, and transplant rejection by administering these agents to mammals.
The binding agents effectively reduce or eliminate TRBC1+cells, providing a targeted method to treat T cell cancers, autoimmune diseases, and transplant rejection, improving treatment outcomes.
Abstract
Description
[0001] Atorney Docket No. 44807-0516WO1 / P18787-02
[0002] METHODS AND MATERIALS FOR TREATING T CELL DISORDERS
[0003] CROSS-REFERENCE TO RELATED APPLICATIONS
[0004] This application claims the benefit of U.S. Patent Application Serial No. 63 / 780,541, filed on March 31, 2025. The disclosure of the prior application is considered part of, and is incorporated by reference in, the disclosure of this application.
[0005] STATEMENT REGARDING FEDERAL FUNDING
[0006] This invention was made with government support under CA270403 awarded by the National Institutes of Health. The government has certain rights in the invention.
[0007] TECHNICAL FIELD
[0008] This document relates to methods and materials for treating T cell disorders. For example, this document provides binding agents (e.g., single-chain variable fragments (scFvs), antigen binding domains, and antibodies) that target (e.g., target and bind) a T cell receptor (TCR) 0 chain constant region 1 (TRBC1) polypeptide. For example, one or more binding agents that target (e.g., target and bind) a TRBC1 polypeptide can be administered to a mammal having a T cell cancer to treat the mammal. For example, one or more binding agents that target (e.g., target and bind) a TRBC1 polypeptide can be administered to a mammal having a T cell driven autoimmune disease to treat the mammal. For example, one or more binding agents that target (e.g., target and bind) a TRBC1 polypeptide can be administered to a mammal experiencing T cell mediated rejection to treat the mammal.
[0009] BACKGROUND
[0010] T cell disorders are a group of conditions that affect the T cells. In some cases, a T cell disorder can include unchecked T cell proliferation such as cancers of the T cell. T cell cancers represent a diverse category of malignancies, accounting for approximately 15% of non-Hodgkin’s lymphomas and 20% of acute lymphoblastic leukemias (ALL) (Swerdlow et al., Blood, 127(20)2375-90 (2016); Han et al., Cancer Causes Control, 19(8):841-58 (2008); and Dores et al., Blood, 119(l):34-43 (2012)). The prognosis for T cell lymphomas and relapsed T cell ALL (T-ALL) is generally poorer compared to their B cell counterparts, withAtorney Docket No. 44807-0516WO1 / P18787-02
[0011] an estimated 5-year survival rate of only 32% for T cell lymphomas and 7% for relapsed T-ALL (Weisenburger et al., Blood, 117( 12):3402-8 (2011) and Fielding et al., Blood, 109(3):944-50 (2007)). In some cases, a T cell disorder can include unchecked T cell activation, in particular activation of self-reactive T cells which recognize and react to a body’s own tissues leading to autoimmune diseases. Such autoreactive T cell disorders include ankylosing spondylitis (affects -300,000 patients per year in US), psoriatic arthritis (20,000 patients per year in US), celiac disease (300,000 patient per year in US), vitiligo (320,000 patients per year in US), Bechet’s disease (16,000 patients per year in US; Reveille, Am J Med Sci, 341(4):284-6 (2011); Gelfand et al., J Am Acad Dermatol, 53(4):573 (2005); Rubio-Tapia et al., Am J Gastroenterol, 107(10): 1538-44 (2012); Mastacouris et al., JAMA Dermatol, 159(9):986-990 (2023); and Hammam et al., Arthritis Res Ther, 23(1):224 (2021)). T cell disorders also include T cell driven rejection of transplanted solid organs such as kidney transplantations (Loupy et al., Am J Transplant, 20(9):2318-2331 (2020)), heart transplantations (Orosz et al., Transplantation, 61 (5):783-91 (1996)), T cell disorders also include T cell mediated pathologies observed after bone marrow transplantations including graft-versus-host disease (Ichiki et al., Autoimmun Rev., 5(1): 1-9 (2006)).
[0012] SUMMARY
[0013] This document provides methods and materials for treating T cell disorders (e.g., T cell cancers, T cell driven autoimmune diseases, and T cell mediated rejection). In some cases, this document provides binding agents (e.g., scFvs, antigen binding domains, and antibodies) that target (e.g., target and bind) a TRBC1 polypeptide (e.g., TRBCU T cell receptor). In some cases, this document provides methods for using binding agents that target (e.g., target and bind) a TRBC1 polypeptide (e.g., TRBCU T cell receptor). For example, a composition including one or more binding agents (e.g., scFvs, antigen binding domains, and antibodies) provided herein (e.g., one or more binding agents that target (e.g., target and bind) a TRBC1 polypeptide) can be administered to a mammal (e.g., a human) having a T cell cancer (e.g., a cancer containing one or more cancer cells expressing a TRBC1 polypeptide, also referred to as TRBC cancer cells) to treat the mammal. For example, a composition including one or more binding agents (e.g., scFvs, antigen binding domains, andAtorney Docket No. 44807-0516WO1 / P18787-02
[0014] antibodies) provided herein (e.g., one or more binding agents that target (e.g., target and bind) a TRBC1 polypeptide can be administered to a mammal having a T cell driven autoimmune disease (e.g., an autoimmune disease driven by one or more TRBC1+T cell receptor expressing T cells that are activated against one or more of the mammal’s own tissues, also referred to as self-activated TRBC1+T cells) to treat the mammal. For example, a composition including one or more binding agents (e.g., scFvs, antigen binding domains, and antibodies) provided herein (e.g., one or more binding agents that target (e.g., target and bind) a TRBC1 polypeptide can be administered to a mammal experiencing T cell mediated rejection (e.g., a transplant rejection where a recipient's TRBCl T cells are activated against a transplanted tissue) to treat the mammal.
[0015] As demonstrated herein, antibodies were designed that target (e.g., target and bind to) a TRBCl polypeptide (e.g., TRBC1+T cell receptor) with little to no binding to a TRBC2 polypeptide (e.g., TRBC2+T cell receptor). Such antibodies can target (e.g., target and destroy) TRBC1+cells. The ability to specifically target TRBC1+cells in a mammal having a T cell cancer (e.g., a cancer containing one or more TRBC1+cancer cells) provides a tumorspecific method to treat T cell cancers. Further, the ability to specifically target TRBC1+cells in mammals having a T cell driven autoimmune disease (e.g., an autoimmune disease driven by one or more self-activated TRBC1+cells) and / or mammals experiencing T cell mediated rejection (e.g., a transplant rejection where a recipient's TRBC l T cells are activated against a transplanted tissue) provides a unique and targeted method to treat other T cell disorders.
[0016] In general, one aspect of this document features binding agents that can bind to a TRBCl polypeptide, wherein said binding agent comprises: (i) a light chain variable domain comprising: a VL CDR1 that comprises or consists essentially of the amino acid sequences set forth in SEQ ID NO: 1, a VL CDR2 that comprises or consists essentially of the amino acid sequences set forth in SEQ ID NO:2, and a VL CDR3 that comprises or consists essentially of the amino acid sequences set forth in SEQ ID NO:3; or (ii) a heavy chain variable domain comprising: a VH CDR1 that comprises or consists essentially of the amino acid sequences set forth in SEQ ID NO:4, a VH CDR2 that comprises or consists essentially of the amino acid sequences set forth in SEQ ID NO:5, and a VH CDR3 that comprises or consists essentially of the amino acid sequences set forth in SEQ ID NO:6. The binding agentAtorney Docket No. 44807-0516WO1 / P18787-02
[0017] can include said light chain variable domain of (i). The light chain variable domain can include an amino acid sequence having at least 90 percent identity to the amino acid sequence set forth in SEQ ID NO: 13. The binding agent can include said heavy chain variable domain of (ii). The heavy chain variable domain can include an amino acid sequence having at least 90 percent identity to the amino acid sequence set forth in SEQ ID NO: 14. The binding agent can include said light chain variable domain of (i) and can include said heavy chain variable domain of (ii). The binding agent can be a single chain variable fragment (scFv), an antigen binding domain, or an antibody. The binding agent can be a monoclonal antibody. In another aspect, this document features nucleic acid encoding such binding agents. The nucleic acid can be in the form of a vector. The vector can be an expression vector. The vector can be a viral vector.
[0018] In another aspect, this document features binding agents that can bind to a TRBC1 polypeptide, wherein said binding agent comprises: (i) a light chain variable domain comprising: a VL CDR1 that comprises or consists essentially of the amino acid sequences set forth in SEQ ID NO:7, a VL CDR2 that comprises or consists essentially of the amino acid sequences set forth in SEQ ID NO:8, and a Vi, CDR3 that comprises or consists essentially of the amino acid sequences set forth in SEQ ID NO:9; or (ii) a heavy chain variable domain comprising: a VH CDR1 that comprises or consists essentially of the amino acid sequences set forth in SEQ ID NO: 10, a VH CDR2 that comprises or consists essentially of the amino acid sequences set forth in SEQ ID NO:11, and a VH CDR3 that comprises or consists essentially of the amino acid sequences set forth in SEQ ID NO: 12. The binding agent can include said light chain variable domain of (i). The light chain variable domain can include an amino acid sequence having at least 90 percent identity to the amino acid sequence set forth in SEQ ID NO: 15. The binding agent can include said heavy chain variable domain of (ii). The heavy chain variable domain can include an amino acid sequence having at least 90 percent identity to the amino acid sequence set forth in SEQ ID NO: 16. The binding agent can include said light chain variable domain of (i) and comprises said heavy chain variable domain of (ii). The binding agent can be a single chain variable fragment (scFv), an antigen binding domain, or an antibody. The binding agent can be a monoclonal antibody. In another aspect, this document features nucleic acid encoding suchAtorney Docket No. 44807-0516WO1 / P18787-02
[0019] binding agents. The nucleic acid can be in the form of a vector. The vector can be an expression vector. The vector can be a viral vector.
[0020] In another aspect, this document features methods for treating a mammal having a T cell cancer. The methods can include, or consist essentially of, administering to a mammal having a T cell cancer, (a) a binding agent that includes: (i) a light chain variable domain comprising: a VL CDR1 that comprises or consists essentially of the amino acid sequences set forth in SEQ ID NO: 1, a VL CDR2 that comprises or consists essentially of the amino acid sequences set forth in SEQ ID NO:2, and a VL CDR3 that comprises or consists essentially of the amino acid sequences set forth in SEQ ID NO:3 (e.g., a light chain variable domain including an amino acid sequence set forth in SEQ ID NO: 13); and / or (ii) a heavy chain variable domain comprising: a VH CDR1 that comprises or consists essentially of the amino acid sequences set forth in SEQ ID NON, a Vn CDR2 that comprises or consists essentially of the amino acid sequences set forth in SEQ ID NO:5, and a VH CDR3 that comprises or consists essentially of the amino acid sequences set forth in SEQ ID NO:6 (e.g., a heavy chain variable domain including an amino acid sequence set forth in SEQ ID NO: 14); (b) a binding agent that includes: (i) a light chain variable domain comprising: a VL CDR1 that comprises or consists essentially of the amino acid sequences set forth in SEQ ID NO:7, a VL CDR2 that comprises or consists essentially of the amino acid sequences set forth in SEQ ID NO: 8, and a VL CDR3 that comprises or consists essentially of the amino acid sequences set forth in SEQ ID NO:9 (e.g., a light chain variable domain including an amino acid sequence set forth in SEQ ID NO: 15); and / or (ii) a heavy chain variable domain comprising: a VH CDR1 that comprises or consists essentially of the amino acid sequences set forth in SEQ ID NO: 10, a Vn CDR2 that comprises or consists essentially of the amino acid sequences set forth in SEQ ID NO: 11, and a VH CDR3 that comprises or consists essentially of the amino acid sequences set forth in SEQ ID NO: 12 (e.g., a heavy chain variable domain including an amino acid sequence set forth in SEQ ID NO: 16); or (c) a nucleic acid encoding a binding agent of (a) or (b), wherein said T cell cancer comprises a cancer cell expressing a TRBC1 polypeptide. The T cell cancer can be acute lymphoblasticAtorney Docket No. 44807-0516WO1 / P18787-02
[0021] leukemia (ALL), peripheral T cell lymphomas (PTCL), angioimmunoblastic T cell lymphomas (AITL), T cell prolymphocytic leukemia (T-PLL), adult T cell leukemia / lymphoma (ATLL), Enteropathy-associated T-cell lymphoma (EATL), monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL), follicular T-cell lymphoma (FTCL), nodal peripheral T-cell lymphoma (nodal PTCL), cutaneous T cell lymphomas (CTCL), anaplastic large cell lymphoma (ALCL), T-cell large granular lymphocytic leukemia (T-LGL), extra nodal NK / T-Cell lymphoma (NKTL), or hepatosplenic T-cell lymphoma. The method can be effective to reduce or eliminate a number of TRBC1+cancer cells within said mammal. The mammal can be a human.
[0022] In another aspect, this document features methods for treating a mammal having a T cell driven autoimmune disease. The methods can include, or consist essentially of, administering to a mammal having a T cell drive autoimmune disease, (a) a binding agent that includes: (i) a light chain variable domain comprising: a VL CDR1 that comprises or consists essentially of the amino acid sequences set forth in SEQ ID NO: 1, a VL CDR2 that comprises or consists essentially of the amino acid sequences set forth in SEQ ID NO:2, and a VL CDR3 that comprises or consists essentially of the amino acid sequences set forth in SEQ ID NO: 3 (e.g., a light chain variable domain including an amino acid sequence set forth in SEQ ID NO: 13); and / or (ii) a heavy chain variable domain comprising: a VH CDR1 that comprises or consists essentially of the amino acid sequences set forth in SEQ ID NO:4, a VH CDR2 that comprises or consists essentially of the amino acid sequences set forth in SEQ ID NO:5, and a VH CDR3 that comprises or consists essentially of the amino acid sequences set forth in SEQ ID NO:6 (e.g., a heavy chain variable domain including an amino acid sequence set forth in SEQ ID NO: 14); (b) a binding agent that includes: (i) a light chain variable domain comprising: a VL CDR1 that comprises or consists essentially of the amino acid sequences set forth in SEQ ID NO:7, a VL CDR2 that comprises or consists essentially of the amino acid sequences set forth in SEQ ID NO:8, and a VL CDR3 that comprises or consists essentially of the amino acid sequences set forth in SEQ ID NO:9 (e.g., a light chain variable domain including an amino acid sequence set forth in SEQ ID NO: 15); and / or (ii) a heavy chain variable domain comprising: a VH CDR1 that comprises or consists essentially of the amino acid sequences set forth in SEQ ID NO: 10, a VH CDR2 that comprises or consistsAtorney Docket No. 44807-0516WO1 / P18787-02
[0023] essentially of the amino acid sequences set forth in SEQ ID NO: 11, and a VH CDR3 that comprises or consists essentially of the amino acid sequences set forth in SEQ ID NO: 12 (e.g., a heavy chain variable domain including an amino acid sequence set forth in SEQ ID NO: 16); or (c) a nucleic acid encoding a binding agent of (a) or (b), wherein said T cell driven autoimmune disease comprises a self-activated T cell expressing a TRBC1 polypeptide. The T cell driven autoimmune disease can be multiple sclerosis (MS), Type 1 diabetes, rheumatoid arthritis, systemic lupus erythematosus (SLE), psoriasis, psoriatic arthritis, ankylosing spondylitis, celiac disease, vitiligo, or Bechet’s disease. The method can be effective to reduce or eliminate a number of self-activated TRBC1+cells within said mammal. The mammal can be a human.
[0024] In another aspect, this document features methods for treating a mammal experiencing T cell mediated rejection. The methods can include, or consist essentially of, administering to a mammal experiencing T cell mediated rejection, (a) a binding agent that includes: (i) a light chain variable domain comprising: a VL CDR1 that comprises or consists essentially of the amino acid sequences set forth in SEQ ID NO:1, a VL CDR2 that comprises or consists essentially of the amino acid sequences set forth in SEQ ID NO:2, and a VL CDR3 that comprises or consists essentially of the amino acid sequences set forth in SEQ ID NO:3 (e.g., a light chain variable domain including an amino acid sequence set forth in SEQ ID NO: 13); and / or (ii) a heavy chain variable domain comprising: a VH CDR1 that comprises or consists essentially of the amino acid sequences set forth in SEQ ID NO:4, a VH CDR2 that comprises or consists essentially of the amino acid sequences set forth in SEQ ID NO:5, and a VH CDR3 that comprises or consists essentially of the amino acid sequences set forth in SEQ ID NO:6 (e.g., a heavy chain variable domain including an amino acid sequence set forth in SEQ ID NO: 14); (b) a binding agent that includes: (i) a light chain variable domain comprising: a VL CDR1 that comprises or consists essentially of the amino acid sequences set forth in SEQ ID NO:7, a VL CDR2 that comprises or consists essentially of the amino acid sequences set forth in SEQ ID NO:8, and a VL CDR3 that comprises or consists essentially of the amino acid sequences set forth in SEQ ID NO:9 (e.g., a light chain variable domain including an amino acid sequence set forth in SEQ ID NO: 15); and / or (ii) a heavy chain variable domain comprising: a VH CDR1 that comprises or consists essentially of theAtorney Docket No. 44807-0516WO1 / P18787-02
[0025] amino acid sequences set forth in SEQ ID NO: 10, a VH CDR2 that comprises or consists essentially of the amino acid sequences set forth in SEQ ID NO: 11, and a VH CDR3 that comprises or consists essentially of the amino acid sequences set forth in SEQ ID NO: 12 (e g., a heavy chain variable domain including an amino acid sequence set forth in SEQ ID NO: 16); or (c) a nucleic acid encoding a binding agent of (a) or (b), wherein said T cell mediated rejection comprises an activated T cell expressing a TRBC1 polypeptide. The T cell mediated rejection can include rejection of an organ transplant or a bone marrow transplant. The method can be effective to reduce or eliminate a number of activated TRBCU cells within said mammal. The mammal can be a human.
[0026] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. Although methods and materials similar or equivalent to those described herein can be used to practice the invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.
[0027] The details of one or more embodiments of the invention are set forth in the accompanying drawings and the description below. Other features, objects, and advantages of the invention will be apparent from the description and drawings, and from the claims.
[0028] BRIEF DESCRIPTION OF THE DRAWINGS
[0029] Figure 1. Schematic of phage display used to identify new antibodies: Generation of TRBC1 -specific antibodies using phage display. The illustration depicts the phage display process, where a phage library was screened against T-cell lines expressing either TRBC1 or TRBC2. Bound phages were eluted, amplified in E. coli, and subjected to massively parallel sequencing (MPS) to analyze the six CDR regions. This allowed for the quantification of unique phage clones that interacted with TRBC1- or TRBC2-expressing cells. The binding and enrichment ratios of each phage clone were then determined (Table 3).Atorney Docket No. 44807-0516WO1 / P18787-02
[0030] Figures 2A-2C: Surface plasmon resonance studies of the indicated TRBC1 antibodies to TRBC1, TRBC2 or CD3 peptides for the JOVI.1-PE antibody (Fig. 2A), the 6R62Y antibody (Fig. 2B), and the 6K62Y antibody (Fig. 2C).
[0031] Figure 3: Binding of the indicated TRBC1 antibodies to normal T cells from human donor assessed by flow cytometry. Human T cells were incubated with JOVI.1-PE antibody along with either 6R62Y antibody or the 6K62Y antibody. 6R62Y and 6K62Y have a C-terminal his tag and anti-His Dy650 was used as a secondary stain for the 6R62Y and 6K62Y antibodies.
[0032] Figure 4: Killing assay with 6K62Y-SG3249 ADCs and 6R62Y-SG3249 ADCs. T cell cancer cell lines were incubated with the indicated concentration of the 6K62Y-SG3249 ADCs and the 6R62Y-SG3249 ADCs for 5 days. The cancer cell viability was measured using a luciferase assay. The IC50 for the 6K62Y-SG3249 ADC and the 6R62Y-SG3249 ADC are indicated in the graphs. Data are mean± standard error of mean of three technical replicates.
[0033] DETAILED DESCRIPTION
[0034] This document provides methods and materials for treating T cell disorders (e.g., T cell cancers, T cell driven autoimmune diseases, and T cell mediated rejection). For example, this document provides binding agents (e.g., scFvs, antigen binding domains, and antibodies) that target (e.g., target and bind) a TRBC1 polypeptide (e.g., TRBC1+T cell receptor). In some cases, a composition including one or more binding agents (e.g., scFvs, antigen binding domains, and antibodies) provided herein (e.g., one or more binding agents that target (e.g., target and bind) a TRBC1 polypeptide) can be administered to a mammal (e.g., a human) having a T cell cancer (e.g., a cancer containing one or more TRBC1+cancer cells) to treat the mammal. In some cases, a composition including one or more binding agents (e.g., scFvs, antigen binding domains, and antibodies) provided herein (e.g., one or more binding agents that target (e.g., target and bind) a TRBC1 polypeptide can be administered to a mammal having a T cell driven autoimmune disease (e.g., an autoimmune disease driven by one or more self-activated TRBC1+cells) to treat the mammal. In some cases, a composition including one or more binding agents (e.g., scFvs, antigen binding domains, and antibodies)Atorney Docket No. 44807-0516WO1 / P18787-02
[0035] provided herein (e.g., a one or more binding agents that target (e.g., target and bind) a TRBC1 polypeptide can be administered to a mammal experiencing T cell mediated rejection (e.g., a transplant rejection where a recipient's TRBC1+T cells are activated against a transplanted tissue) to treat the mammal.
[0036] A binding agent (e.g., an scFv, an antigen binding domain, or an antibody) provided herein (e.g., a binding agent that can target (e.g., target and bind) a TRBC1 polypeptide) can bind any appropriate TRBC1 polypeptide. Examples of TRBC1 polypeptides include, without limitation, those set forth in the international ImMunoGeneTics (IMGT) databases at Accession Nos. M12887, L36092, IMGT000021, ENSG00000211751, and ENSG00000281981.
[0037] In some cases, a binding agent (e.g., an scFv, an antigen binding domain, or an antibody) provided herein (e.g., a binding agent that can target (e.g., target and bind) a TRBC1 polypeptide) does not target (e.g., does not bind to) a TRBC2 polypeptide.
[0038] In some cases, a binding agent (e.g., an scFv, an antigen binding domain, or an antibody) provided herein (e.g., a binding agent that can target (e.g., target and bind) a TRBC1 polypeptide) minimally binds to a TRBC2 polypeptide. For example, a binding agent provided herein can bind to a TRBC2 polypeptide with a low affinity (e.g., an affinity of about 90 nM or less).
[0039] A binding agent (e.g., an scFv, an antigen binding domain, or an antibody) provided herein (e.g., a binding agent that can target (e.g., target and bind) a TRBC1 polypeptide) can be any type of molecule that can bind a TRBC1 polypeptide. Examples of types of molecules that can bind a TRBC1 polypeptide include, without limitation, scFvs, antigen binding domains, and antibodies.
[0040] A binding agent (e.g., an scFv, an antigen binding domain, or an antibody) provided herein (e.g., a binding agent that can target (e.g., target and bind) a TRBC1 polypeptide) can include a variable domain of an immunoglobulin light chain (VL) and / or a variable domain of an immunoglobulin heavy chain (VH). For example, a binding agent provided herein can include a first complementarity determining region (CDR) from an immunoglobulin light chain (a VL CDR1), a second CDR from an immunoglobulin light chain (a VL CDR2), and a third CDR an immunoglobulin light chain (a VL CDR3), a first CDR from anAttorney Docket No. 44807-0516WO1 / P18787-02
[0041] immunoglobulin heavy chain (a VH CDR1), a second CDR from an immunoglobulin heavy chain (a VH CDR2), and a third CDR an immunoglobulin heavy chain (a VH CDR3).
[0042] In some cases, a binding agent (e.g., an scFv, an antigen binding domain, or an antibody) provided herein (e.g., a binding agent that can target (e.g., target and bind) a TRBC1 polypeptide) can include CDRs that comprise, consist essentially of, or consist of the CDR amino acid sequences set forth in Table 1 and / or Table 2:
[0043] Table 1. Exemplary CDR sequences for a binding agent that can target a TRBC1 polypeptide.
[0044] Sequence SEQ ID NO VL CDR1 RSSQNLRHSNGRTYLQ 1 VL CDR2 RVSNRFP 2 VL CDR3 SQSTHVPYT 3 VH CDR1 PRGFHGYHMH 4 VH CDR2 FINPYNDDIQSNERFRG 5
[0045] GNGYWGDGAYR
[0046]
[0047] VH CDR3 FFDF 6
[0048] Table 2. Exemplary CDR sequences for a binding agent that can target a TRBC1 polypeptide.
[0049] Sequence SEQ ID NO VL CDR1 RSSQNLRHSNGRTYLQ 7 VL CDR2 RVSNRFP 8 VL CDR3 SQSTHVPYT 9 VH CDR1 PRGFHGYHMH 10 VH CDR2 FINPYNDDIQSNERFRG 11 VH CDR3 GNGYWGDGAYRFFDF
[0050]
[0051] 12
[0052] A CDR that can be included in a binding agent (e.g., an scFv, an antigen binding domain, or an antibody) provided herein (e.g., a binding agent that can target (e.g., target and bind) a TRBC1 polypeptide) that consists essentially of a CDR amino acid sequence set forth in any one of SEQ ID NOs:l-12 is a CDR that has zero, one, or two amino acid substitutions within the articulated sequence of the sequence identifier (e.g., SEQ ID NOs:l-12), has zero, one, two, three, four, or five amino acid residues preceding the articulated sequence of the sequence identifier (e.g., SEQ ID NOs: 1-12), and / or has zero, one, two, three, four, or fiveAtorney Docket No. 44807-0516WO1 / P18787-02
[0053] amino acid residues following the articulated sequence of the sequence identifier (e.g., SEQ ID NOs: 1-12), provided that the binding agent retains the ability to target (e.g., target and bind to) a TRBC1 polypeptide (e.g., TRBC1+T cell receptor).
[0054] In some cases, a binding agent (e.g., an scFv, an antigen binding domain, or an antibody) provided herein (e.g., a binding agent that can target (e.g., target and bind) a TRBC1 polypeptide) can have one or more CDRs that are not 100% identical to the CDRs set forth in any one of SEQ ID NOs: 1-12, but retain the ability to bind to a TRBC1 polypeptide. For example, a CDR that includes one or more (e.g., one, two, three, four, five, or more) amino acid substitutions relative to a CDR set forth in any one of SEQ ID NOs: 1-12 can be used in a binding agent provided herein. An amino acid substitution can be made, in some cases, by selecting a substitution that does not differ significantly in its effect on maintaining (a) the structure of the peptide backbone in the area of the substitution, (b) the charge or hydrophobicity of the molecule at particular sites, or (c) the bulk of the side chain. For example, naturally occurring residues can be divided into groups based on side-chain properties: (1) hydrophobic amino acids (methionine, alanine, valine, leucine, and isoleucine); (2) neutral hydrophilic amino acids (cysteine, serine, and threonine); (3) acidic amino acids (aspartic acid and glutamic acid); (4) basic amino acids (asparagine, glutamine, histidine, lysine, and arginine); (5) amino acids that influence chain orientation (glycine and proline); and (6) aromatic amino acids (tryptophan, tyrosine, and phenylalanine).
[0055] Substitutions made within these groups can be considered conservative substitutions. Nonlimiting examples of conservative substitutions that can be made within a CDR of a binding agent provided herein include, without limitation, substitution of valine for alanine, lysine for arginine, glutamine for asparagine, glutamic acid for aspartic acid, serine for cysteine, asparagine for glutamine, aspartic acid for glutamic acid, proline for glycine, arginine for histidine, leucine for isoleucine, isoleucine for leucine, arginine for lysine, leucine for methionine, leucine for phenyalanine, glycine for proline, threonine for serine, serine for threonine, tyrosine for tryptophan, phenylalanine for tyrosine, and / or leucine for valine.
[0056] In some cases, a binding agent (e.g., an scFv, an antigen binding domain, or an antibody) provided herein (e.g., a binding agent that can target (e.g., target and bind) a TRBC1 polypeptide) can include a light chain having a VL CDR1 comprising, consistingAtorney Docket No. 44807-0516WO1 / P18787-02
[0057] essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 1, a VL CDR2 comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:2, and a VL CDR3 comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:3. For example, a binding agent that can target (e.g., target and bind) a TRBC1 polypeptide (e.g., TRBC1+T cell receptor) can include a light chain including the amino acid sequence set forth in SEQ ID NO: 13.
[0058] In some cases, a binding agent (e.g., an scFv, an antigen binding domain, or an antibody) provided herein (e.g., a binding agent that can target (e.g., target and bind) a TRBC1 polypeptide) can include a heavy chain having a VH CDR1 comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:4, a VH CDR2 comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 5, and a VH CDR3 comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:6. For example, a binding agent that can target (e.g., target and bind) a TRBC1 polypeptide (e.g., TRBC1+T cell receptor) can include a heavy chain including the amino acid sequence set forth in SEQ ID NO: 14.
[0059] In some cases, a binding agent (e.g., an scFv, an antigen binding domain, or an antibody) provided herein (e.g., a binding agent that can target (e.g., target and bind) TRBC1 polypeptide) can include a light chain having a VL CDR1 including the amino acid sequence set forth in SEQ ID NO: 1, a VL CDR2 including the amino acid sequence set forth in SEQ ID NO:2, and a VL CDR3 including the amino acid sequence set forth in SEQ ID NO:3, and can include a heavy chain having a VH CDR1 including the amino acid sequence set forth in SEQ ID NO:4, a VH CDR2 including the amino acid sequence set forth in SEQ ID NO:5, and a VH CDR3 including the amino acid sequence set forth in SEQ ID NO:6. For example, a binding agent that can target (e.g., target and bind) a TRBC1 polypeptide (e.g., TRBC1+T cell receptor) can include a light chain including the amino acid sequence set forth in SEQ ID NO: 13 and can include a heavy chain including the amino acid sequence set forth in SEQ ID NO:14.
[0060] In some cases, a binding agent (e.g., an scFv, an antigen binding domain, or an antibody) provided herein (e.g., a binding agent that can target (e.g., target and bind) a TRBC1 polypeptide) can include a light chain having a VL CDR1 comprising, consistingAtorney Docket No. 44807-0516WO1 / P18787-02
[0061] essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:7, a VL CDR2 comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 8, and a VL CDR3 comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:9. For example, a binding agent that can target (e.g., target and bind) a TRBC1 polypeptide (e.g., TRBC1+T cell receptor) can include a light chain including the amino acid sequence set forth in SEQ ID NO: 15.
[0062] In some cases, a binding agent (e.g., an scFv, an antigen binding domain, or an antibody) provided herein (e.g., a binding agent that can target (e.g., target and bind) a TRBC1 polypeptide) can include a heavy chain having a VH CDR1 comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 10, a VH CDR2 comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 11, and a VH CDR3 comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO: 12. For example, a binding agent that can target (e.g., target and bind) a TRBC1 polypeptide (e.g., TRBC1+T cell receptor) can include a heavy chain including the amino acid sequence set forth in SEQ ID NO: 16.
[0063] In some cases, a binding agent (e.g., an scFv, an antigen binding domain, or an antibody) provided herein (e.g., a binding agent that can target (e.g., target and bind) a TRBC1 polypeptide) can include a light chain having a VL CDR1 including the amino acid sequence set forth in SEQ ID NO: 7, a VL CDR2 including the amino acid sequence set forth in SEQ ID NO: 8, and a VL CDR3 including the amino acid sequence set forth in SEQ ID NOV, and can include a heavy chain having a VH CDR1 including the amino acid sequence set forth in SEQ ID NO: 10, a VH CDR2 including the amino acid sequence set forth in SEQ ID NO: 11, and a VH CDR3 including the amino acid sequence set forth in SEQ ID NO: 12. For example, a binding agent that can target (e.g., target and bind) a TRBC1 polypeptide (e.g., TRBC1+T cell receptor) can include a light chain including the amino acid sequence set forth in SEQ ID NO: 15 and can include a heavy chain including the amino acid sequence set forth in SEQ ID NO: 16.
[0064] A binding agent (e.g., an scFv, an antigen binding domain, or an antibody) provided herein (e.g., a binding agent that can target (e.g., target and bind) a TRBC1 polypeptide) can include any appropriate framework regions. In some cases, a binding agent provided hereinAtorney Docket No. 44807-0516WO1 / P18787-02
[0065] can include the framework regions shown in Example 2. For example, a binding agent provided herein that includes the CDRs set forth in any one of SEQ ID NOs: 1-6 can be designed to include (a) a VL that includes the framework regions set forth in SEQ ID NO: 13 and / or (b) a VH that includes the framework regions set forth in SEQ ID NO: 14. For example, a binding agent provided herein that includes the CDRs set forth in any one of SEQ ID NOs:7-12 can be designed to include (a) a VL that includes the framework regions set forth in SEQ ID NO: 15 and / or (b) a VH that includes the framework regions set forth in SEQ ID NO: 16. In some cases, a binding agent provided herein can include one or more framework regions from another scFv, antigen binding domain, or antibody. For example, a binding agent provided herein can include the framework regions described elsewhere (see, e.g., Pascalis et al., J Immunol, 169(6):3076-84 (2002); Jones et al., Nature, 321(6069):522-5 (1986); and Kim et al., Methods Mol Biol, 907:237-45 (2012)).
[0066] In some cases, when a binding agent (e.g., an scFv, an antigen binding domain, or an antibody) provided herein (e.g., a binding agent that can target (e.g., target and bind) a TRBC1 polypeptide) includes a VL and a VH, the VL and the VH can be directly conjugated.
[0067] In some cases, when a binding agent (e.g., an scFv, an antigen binding domain, or an antibody) provided herein (e.g., a binding agent that can target (e.g., target and bind) a TRBC1 polypeptide) includes a VL and a VH, the VL and the VH can be indirectly conjugated. For example, a VL and VH can be connected via a linker such as a peptide linker to produce a binding agent provided herein.
[0068] This document also provides molecules that include one or more binding agents (e.g., scFvs, antigen binding domains, and antibodies) provided herein (e.g., a one or more binding agents that target (e.g., target and bind) a TRBC1 polypeptide). Examples of molecules that one or more binding agents provided herein can be included in include, without limitation, antibody-drug conjugates (ADCs), chimeric antigen receptors (CARs), bispecific binders (e.g., cell engagers such as T cell engagers and natural killer (NK) cell engagers). In cases when a binding agent provided herein is in the form of an ADC, the binding agent can be conjugated to one or more drugs (e.g., one or more anti-cancer agents such as cytotoxic agents). Examples of drugs that can be used to make an ADC described herein include, without limitation, auristatins (e.g., monomethyl auristatin E (MMAE) and monomethylAtorney Docket No. 44807-0516WO1 / P18787-02
[0069] auristatin F (MMAF)), mertansine (DM-1), pyrrol obenzodiazepine (PBD) dimers, DM4, N-Acetyl-calicheamicin, duocarmycin, DXd, and SN38. In some cases, a drug that can be used to make an ADC described herein can be as described in International Patent Application Publication No. WO 2025 / 007013.
[0070] In cases when a binding agent provided herein is in the form of a CAR, the binding agent can be included in any appropriate CAR. Examples of CARs that can include one or more binding agents provided herein can be as described in U.S. Provisional Patent Application No. 63 / 693,394, filed September 11, 2024.
[0071] In cases when a binding agent provided herein is in the form of a bispecific binder (e.g., a cell engager such as a T cell engager or a NK cell engager), the binding agent can be included in any appropriate bispecific binder. Examples of bispecific binders that can include one or more binding agents provided herein can be as described in International Patent Application Publication No. WO 2022 / 177889 and U.S. Provisional Patent Application No.
[0072] 63 / 693,408, filed September 11, 2024.
[0073] Also provided herein are nucleic acid molecules encoding a binding agent (e.g., an scFv, an antigen binding domain, or an antibody) provided herein (e.g., a binding agent that can target (e.g., target and bind) a TRBC1 polypeptide). In some cases, a nucleic acid that can encode a binding agent provided herein can be in the form of a vector (e.g., a viral vector or a non-viral vector). When a vector including nucleic acids encoding a binding agent provided herein is a viral vector, any appropriate viral vector can be used. A viral vector can be derived from a positive-strand virus or a negative-strand virus. A viral vector can be derived from a virus with a DNA genome or an RNA genome. In some cases, a viral vector can be a chimeric viral vector. In some cases, a viral vector can infect dividing cells. In some cases, a viral vector can be replication-defective. In some cases, a viral vector can infect nondividing cells. Examples virus-based vectors that can include nucleic acid encoding a binding agent provided herein include, without limitation, lentiviral vectors, retroviral vectors, and adeno-associated viral vectors. When a vector including nucleic acid encoding a binding agent provided herein is a non-viral vector, any appropriate non-viral vector can be used. In some cases, a non-viral vector can be an expression plasmid (e.g., a cDNA expression vector).Atorney Docket No. 44807-0516WO1 / P18787-02
[0074] This document also provides methods and materials involved in treating T cell disorders (e.g., T cell cancers, T cell driven autoimmune diseases, and T cell mediated rejection). For example, one or more binding agents (e.g., scFvs, antigen binding domains, and antibodies) provided herein (e.g., a binding agent that can target (e.g., target and bind) a TRBC1 polypeptide) can be administered to a mammal (e.g., a human) having one or more T cell disorders to treat the mammal. In some cases, a composition including one or more binding agents (e.g., scFvs, antigen binding domains, and antibodies) provided herein (e.g., one or more binding agents that target (e.g., target and bind) a TRBC1 polypeptide) can be administered to a mammal (e g., a human) having a T cell cancer (e.g., a cancer containing one or more TRBC1+cancer cells) to treat the mammal. In some cases, a composition including one or more binding agents (e.g., scFvs, antigen binding domains, and antibodies) provided herein (e g., one or more binding agents that target (e.g., target and bind) a TRBC1 polypeptide (e.g., TRBC1+T cell receptor) can be administered to a mammal having a T cell driven autoimmune disease (e.g., an autoimmune disease driven by one or more selfactivated TRBC1+cells) to treat the mammal.
[0075] In some cases, one or more binding agents (e.g., scFvs, antigen binding domains, and antibodies) provided herein (e.g., a binding agent that can target (e.g., target and bind) a TRBC1 polypeptide) can be administered to a mammal (e.g., a human) in need thereof (e.g., a human having a T cell cancer (e.g., a cancer containing one or more cancer cells expressing a TRBC1 polypeptide) and / or a T cell driven autoimmune disease (e.g., an autoimmune disease driven by one or more self-activated TRBC1+cells)) to reduce or eliminate the number of TRBC1+cells within the mammal. For example, the materials and methods described herein can be used to reduce the number of TRBC1+cells within a mammal by, for example, 10, 20, 30, 40, 50, 60, 70, 80, 90, 95, or more percent. In some cases, the materials and methods described herein can be used to reduce or eliminate the number of TRBC1+cancer cells within a mammal having a T cell cancer. In some cases, the materials and methods described herein can be used to reduce or eliminate the number of self-activated TRBC1+cells within a mammal having T cell driven autoimmune disease.
[0076] Any appropriate mammal (e.g., a human) having one or more T cell disorders (e.g., a T cell cancer (e.g., a cancer containing one or more TRBC1+cancer cells), a T cell drivenAtorney Docket No. 44807-0516WO1 / P18787-02
[0077] autoimmune disease (e.g., an autoimmune disease driven by one or more self-activated TRBC1+cells), and / or a T cell mediated rejection (e.g., a transplant rejection where a recipient's TRBC1+T cells are activated against a transplanted tissue)) can be treated as described herein (e.g., by administering one or more binding agents (e.g., scFvs, antigen binding domains, and antibodies) provided herein (e.g., a binding agent that can target (e.g., target and bind) a TRBC1 polypeptide). Examples of mammals that can be treated as described herein include, without limitation, humans, primates (such as monkeys), dogs, cats, horses, cows, pigs, sheep, mice, and rats. In some cases, a human having a T cell cancer (e.g., a cancer containing one or more TRBC1+cancer cells) can be treated with one or more binding agents that can target (e.g., target and bind) a TRBC1 polypeptide (e.g., TRBC1+T cell receptor). In some cases, a human having a T cell driven autoimmune disease (e.g., an autoimmune disease driven by one or more self-activated TRBC1+cells) can be treated with one or more binding agents that can target (e.g., target and bind) a TRBC1 polypeptide.
[0078] When treating a mammal (e.g., a human) having a T cell cancer (e.g., a cancer containing one or more TRBC1+cancer cells) as described herein, the T cell cancer can be any type of T cell cancer. In some cases, a T cell cancer can include a clonal T cell expansion. In some cases, a T cell cancer can include one or more solid tumors. In some cases, a T cell cancer can be a blood cancer. In some cases, a T cell cancer can be a primary cancer. In some cases, a T cell cancer can be a recurrent cancer. In some cases, a T cell cancer can be a metastatic cancer. In some cases, a T cell cancer can be a refractory cancer. In some cases, a T cell cancer can be a non-Hodgkin’s lymphoma. Examples of T cell cancers that can be treated as described herein include, without limitation, acute lymphoblastic leukemia (ALL), peripheral T cell lymphomas (PTCL), angioimmunoblastic T cell lymphomas (A1TL), T cell prolymphocytic leukemia (T-PLL), adult T cell leukemia / lymphoma (ATLL), Enteropathy-associated T-cell lymphoma (EATL), monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL), follicular T-cell lymphoma (FTCL), nodal peripheral T-cell lymphoma (nodal PTCL), cutaneous T cell lymphomas (CTCL), anaplastic large cell lymphoma (ALCL), T-cell large granular lymphocytic leukemia (T-LGL), extra nodal NK / T-Cell lymphoma (NKTL), and hepatosplenic T-cell lymphoma.Atorney Docket No. 44807-0516WO1 / P18787-02
[0079] In some cases, the materials and methods provided herein can be used to reduce or eliminate the number of cancer cells (e.g., TRBC1+cancer cells) present within a mammal (e.g., a human) having a T cell cancer (e.g., a cancer containing one or more TRBC1+cancer cells). For example, a mammal in need thereof (e.g., a mammal having a T cell cancer) can be administered one or more binding agents (e.g., scFvs, antigen binding domains, and antibodies) provided herein (e.g., a binding agent that can target (e.g., target and bind) a TRBC1 polypeptide) to reduce or eliminate the number of TRBC1+cancer cells present within the mammal. For example, the materials and methods described herein can be used to reduce the number of TRBC1+cancer cells present within a mammal having a T cell cancer by, for example, 10, 20, 30, 40, 50, 60, 70, 80, 90, 95, or more percent. For example, the materials and methods described herein can be used to reduce the size (e.g., volume) of one or more tumors present within a mammal having a T cell cancer by, for example, 10, 20, 30, 40, 50, 60, 70, 80, 90, 95, or more percent. In some cases, the number of TRBC1+cancer cells present within a mammal being treated can be monitored. Any appropriate method can be used to determine whether or not the number of cancer cells present within a mammal is reduced. For example, imaging techniques can be used to assess the number of cancer cells present within a mammal.
[0080] In some cases, the materials and methods provided herein can be used to improve survival of a mammal (e.g., a human) having a T cell cancer (e.g., a cancer containing one or more TRBC1+cancer cells). For example, a mammal in need thereof (e.g., a mammal having a T cell cancer) can be administered one or more binding agents (e.g., scFvs, antigen binding domains, and antibodies) provided herein (e.g., a binding agent that can target (e.g., target and bind) a TRBC1 polypeptide) to improve survival of the mammal. For example, the materials and methods described herein can be used to improve the survival of a mammal having a T cell cancer by, for example, 10, 20, 30, 40, 50, 60, 70, 80, 90, 95, or more percent. For example, the materials and methods described herein can be used to improve the survival of a mammal having a T cell cancer by, for example, at least 6 months (e.g., about 6 months, about 8 months, about 10 months, about 1 year, about 1.5 years, about 2 years, about 2.5 years, about 3 years, about 4 years, about 5 years, or more).Atorney Docket No. 44807-0516WO1 / P18787-02
[0081] In some cases, the methods described herein also can include identifying a mammal as having a T cell cancer (e.g., a cancer containing one or more TRBC1+cancer cells).
[0082] Examples of methods for identifying a mammal as having a T cell cancer include, without limitation, physical examination, laboratory tests (e.g., blood and / or urine), biopsy, imaging tests (e.g., X-ray, PET / CT, MRI, and / or ultrasound), nuclear medicine scans (e.g., bone scans), endoscopy, and / or genetic tests. Once identified as having a T cell cancer, a mammal can be administered or instructed to self-administer one or more binding agents (e.g., scFvs, antigen binding domains, and antibodies) provided herein (e.g., a binding agent that can target (e.g., target and bind) a TRBC1 polypeptide).
[0083] When treating a mammal (e.g., a human) having a T cell driven autoimmune disease (e.g., an autoimmune disease driven by one or more self-activated TRBC1+cells) as described herein, the T cell driven autoimmune disease can be any type of T cell driven autoimmune disease. In some cases, a T cell driven autoimmune disease can include a clonal T cell expansion. Examples of T cell driven autoimmune diseases that can be treated as described herein include, without limitation, multiple sclerosis (MS), Type 1 diabetes, rheumatoid arthritis, systemic lupus erythematosus (SLE), psoriasis, psoriatic arthritis, ankylosing spondylitis, celiac disease, vitiligo, and Bechet’s disease.
[0084] When treating a mammal (e.g., a human) experiencing T cell mediated rejection (e.g., a transplant rejection where a recipient's TRBC1+T cells are activated against a transplanted tissue) as described herein, the T cell mediated rejection can be any type of T cell mediated rejection. Any type of transplant can be rejected by T cell mediated rejection. Examples of transplants that can be rejected by T cell mediated rejection include, without limitation, organ transplants (e.g., kidney transplants, heart transplants, and lung transplants) and tissue transplants (e.g., bone marrow transplants. In some cases, the methods and materials provided herein can be used to treat a complication associated with a transplant such as graft-versus-host disease.
[0085] In some cases, the materials and methods provided herein can be used to reduce or eliminate the number of activated TRBC1+cells (e.g., self-activated TRBC1+cells) present within a mammal (e.g., a human) having a T cell driven autoimmune disease (e.g., an autoimmune disease driven by one or more self-activated TRBC1+cells) or within a mammalAtorney Docket No. 44807-0516WO1 / P18787-02
[0086] (e.g., a human) experiencing a T cell mediated rejection (e.g., a transplant rejection where a recipient's TRBC1+T cells are activated against a transplanted tissue). For example, a mammal in need thereof (e.g., a mammal having a T cell driven autoimmune disease and / or experiencing T cell mediated rejection) can be administered one or more binding agents (e.g., scFvs, antigen binding domains, and antibodies) provided herein (e.g., a binding agent that can target (e.g., target and bind) a TRBC1 polypeptide) to reduce or eliminate the number of activated TRBC1+cells (e.g., self-activated TRBC1+cells) present within the mammal. For example, the materials and methods described herein can be used to reduce the number of activated TRBC1+cells present within a mammal having a T cell driven autoimmune disease and / or experiencing T cell mediated rejection by, for example, 10, 20, 30, 40, 50, 60, 70, 80, 90, 95, or more percent. In some cases, the number of activated TRBC1+cells present within a mammal being treated can be monitored. Any appropriate method can be used to determine whether or not the number of activated TRBC1+cells (e.g., self-activated TRBC1+cells) present within a mammal is reduced. For example, flow cytometry, immunohistochemistry, and / or nucleic acid (e.g., DNA and RNA) sequencing can be used to assess the number of activated TRBC1+cells present within a mammal.
[0087] In some cases, the methods described herein also can include identifying a mammal as having a T cell driven autoimmune disease (e.g., an autoimmune disease driven by one or more self-activated TRBC1+cells) and / or as experiencing T cell mediated rejection (e.g., a transplant rejection where a recipient's TRBC1+T cells are activated against a transplanted tissue). Examples of methods for identifying a mammal as having a T cell driven autoimmune disease include, without limitation, flow cytometry, immunohistochemistry, and / or nucleic acid (e.g., DNA and RNA) sequencing. Once identified as having a T cell driven autoimmune disease, a mammal can be administered or instructed to self-administer one or more binding agents (e.g., scFvs, antigen binding domains, and antibodies) provided herein (e.g., a binding agent that can target (e.g., target and bind) a TRBC1 polypeptide).
[0088] A mammal having one or more T cell disorders (e.g., a T cell cancer (e.g., a cancer containing one or more TRBC1+cancer cells), a T cell driven autoimmune disease (e.g., an autoimmune disease driven by one or more self-activated TRBC1+cells), and / or a T cell mediated rejection (e.g., a transplant rejection where a recipient's TRBC1+T cells areAtorney Docket No. 44807-0516WO1 / P18787-02
[0089] activated against a transplanted tissue)) can be administered or instructed to self-administer one or more (e.g., one, two, three, four, or more) binding agents (e.g., scFvs, antigen binding domains, and antibodies) provided herein (e.g., a binding agent that can target (e.g., target and bind) a TRBC1 polypeptide).
[0090] Any appropriate amount (e.g., any appropriate dose) of one or more binding agents (e.g., scFvs, antigen binding domains, and antibodies) provided herein (e.g., a binding agent that can target (e.g., target and bind) a TRBC1 polypeptide) can be administered to a mammal (e.g., a human) having one or more T cell disorders (e.g., a T cell cancer (e.g., a cancer containing one or more TRBC1+cancer cells), a T cell driven autoimmune disease (e.g., an autoimmune disease driven by one or more self-activated TRBC1+cells), and / or a T cell mediated rejection (e.g., a transplant rejection where a recipient's TRBC1+T cells are activated against a transplanted tissue)). For example, an effective amount of a binding agent provided herein and having a light chain having a VL CDR1 including the amino acid sequence set forth in SEQ ID NO: 1, a VL CDR2 including the amino acid sequence set forth in SEQ ID NO:2, and a VL CDR3 including the amino acid sequence set forth in SEQ ID NO:3 (e.g., a VL having the sequence set forth in SEQ ID NO: 13), and having a heavy chain having a VH CDR1 including the amino acid sequence set forth in SEQ ID NO:4, a VH CDR2 including the amino acid sequence set forth in SEQ ID NO:5, and a VH CDR3 including the amino acid sequence set forth in SEQ ID NO: 6 (e.g., a VH having the sequence set forth in SEQ ID NO: 14) can be any amount that can treat a mammal having cancer (e.g., a cancer containing one or more cancer cells expressing a TRBC1 polypeptide) as described herein without producing significant toxicity to the mammal. For example, an effective amount of a binding agent provided herein and having a light chain having a VL CDR1 including the amino acid sequence set forth in SEQ ID NO:7, a VL CDR2 including the amino acid sequence set forth in SEQ ID NO: 8, and a VL CDR3 including the amino acid sequence set forth in SEQ ID NO:9 (e.g., a VL having the sequence set forth in SEQ ID NO: 15), and having a heavy chain having a VH CDR1 including the amino acid sequence set forth in SEQ ID NO: 10, a VH CDR2 including the amino acid sequence set forth in SEQ ID NO: 11, and a VH CDR3 including the amino acid sequence set forth in SEQ ID NO: 12 (e.g., a VH having the sequence set forth in SEQ ID NO: 16) can be any amount that can treat a mammal havingAtorney Docket No. 44807-0516WO1 / P18787-02
[0091] cancer (e.g., a cancer containing one or more cancer cells expressing a TRBC1 polypeptide) as described herein without producing significant toxicity to the mammal. The effective amount can remain constant or can be adjusted as a sliding scale or variable dose depending on the mammal’s response to treatment. Various factors can influence the actual effective amount used for a particular application. For example, the frequency of administration, duration of treatment, use of multiple treatment agents, route of administration, and / or severity of the cancer in the mammal being treated may require an increase or decrease in the actual effective amount administered.
[0092] One or more binding agents (e.g., scFvs, antigen binding domains, and antibodies) provided herein (e.g., a binding agent that can target (e.g., target and bind) a TRBC1 polypeptide) can be administered to a mammal (e.g., a human) having one or more T cell disorders (e.g., a T cell cancer (e.g., a cancer containing one or more TRBC1+cancer cells), a T cell driven autoimmune disease (e.g., an autoimmune disease driven by one or more selfactivated TRBC1+cells), and / or a T cell mediated rejection (e.g., a transplant rejection where a recipient's TRBC1+T cells are activated against a transplanted tissue)) in any appropriate frequency. The frequency of administration can be any frequency that can treat a mammal having one or more T cell disorders without producing significant toxicity to the mammal. For example, the frequency of administration can be from about once a day to about once a week, from about once a week to about once a month, or from about twice a month to about once a month. The frequency of administration can remain constant or can be variable during the duration of treatment. As with the effective amount, various factors can influence the actual frequency of administration used for a particular application. For example, the effective amount, duration of treatment, use of multiple treatment agents, and / or route of administration may require an increase or decrease in administration frequency.
[0093] One or more binding agents (e.g., scFvs, antigen binding domains, and antibodies) provided herein (e g., a binding agent that can target (e.g., target and bind) a TRBC1 polypeptide) can be administered to a mammal (e.g., a human) having one or more T cell disorders (e.g., a T cell cancer (e.g., a cancer containing one or more TRBC1+cancer cells), a T cell driven autoimmune disease (e.g., an autoimmune disease driven by one or more selfactivated TRBC1+cells), and / or a T cell mediated rejection (e.g., a transplant rejection whereAtorney Docket No. 44807-0516WO1 / P18787-02
[0094] a recipient's TRBC1 T cells are activated against a transplanted tissue)) for any appropriate duration. An effective duration for administering or using a composition containing one or more binding agents provided herein can be any duration that can treat a mammal having one or more T cell disorders without producing significant toxicity to the mammal. For example, the effective duration can vary from several weeks to several months, from several months to several years, or from several years to a lifetime. Multiple factors can influence the actual effective duration used for a particular treatment. For example, an effective duration can vary with the frequency of administration, effective amount, use of multiple treatment agents, and / or route of administration.
[0095] In some cases, one or more binding agents (e.g., scFvs, antigen binding domains, and antibodies) provided herein (e.g., a binding agent that can target (e.g., target and bind) a TRBC1 polypeptide) can be formulated into a composition (e.g., a pharmaceutically acceptable composition) for administration to a mammal (e.g., a human) having one or more T cell disorders (e.g., a T cell cancer (e.g., a cancer containing one or more TRBC1+cancer cells), a T cell driven autoimmune disease (e.g., an autoimmune disease driven by one or more self-activated TRBC1+cells), and / or a T cell mediated rejection (e.g., a transplant rejection where a recipient's TRBC1+T cells are activated against a transplanted tissue)). For example, one or more binding agents provided herein can be formulated together with one or more pharmaceutically acceptable carriers (additives), excipients, and / or diluents. Examples of pharmaceutically acceptable carriers, excipients, and diluents that can be used in a composition described herein include, without limitation, cyclodextrins (e.g., betacyclodextrins such as KLEPTOSE®), dimethylsulfoxide (DMSO), sucrose, lactose, starch (e g., starch glycolate), cellulose, cellulose derivatives (e.g., modified celluloses such as microcrystalline cellulose, and cellulose ethers like hydroxypropyl cellulose (HPC) and cellulose ether hydroxypropyl methylcellulose (HPMC)), xylitol, sorbitol, mannitol, gelatin, polymers (e.g., polyvinylpyrrolidone (PVP), polyethylene glycol (PEG), crosslinked polyvinylpyrrolidone (crospovidone), carboxymethyl cellulose, polyethylene-polyoxypropylene-block polymers, and crosslinked sodium carboxymethyl cellulose (croscarmellose sodium)), titanium oxide, azo dyes, silica gel, fumed silica, talc, magnesium carbonate, vegetable stearin, magnesium stearate, aluminum stearate, stearic acid,Atorney Docket No. 44807-0516WO1 / P18787-02
[0096] antioxidants (e.g., vitamin A, vitamin E, vitamin C, retinyl palmitate, and selenium), citric acid, sodium citrate, parabens (e.g., methyl paraben and propyl paraben), petrolatum, dimethyl sulfoxide, mineral oil, serum proteins (e.g., human serum albumin), glycine, sorbic acid, potassium sorbate, water, salts or electrolytes (e.g., saline, protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, and zinc salts), colloidal silica, magnesium trisilicate, polyacrylates, waxes, wool fat, lecithin, and com oil.
[0097] In some cases, when a composition containing one or more binding agents (e.g., scFvs, antigen binding domains, and antibodies) provided herein (e.g., a binding agent that can target (e.g., target and bind) a TRBC1 polypeptide) is administered to a mammal (e.g., a human) having one or more T cell disorders (e.g., a T cell cancer (e.g., a cancer containing one or more TRBC1+cancer cells), a T cell driven autoimmune disease (e.g., an autoimmune disease driven by one or more self-activated TRBC1+cells), and / or a T cell mediated rejection (e.g., a transplant rejection where a recipient's TRBCT T cells are activated against a transplanted tissue)), the composition can be designed for oral or parenteral (including, without limitation, a subcutaneous, intramuscular, intravenous, intradermal, intra-cerebral, intrathecal, or intraperitoneal (i.p.) injection) administration to the mammal. Compositions suitable for oral administration include, without limitation, liquids, tablets, capsules, pills, powders, gels, and granules. Compositions suitable for parenteral administration include, without limitation, aqueous and non-aqueous sterile injection solutions that can contain antioxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient.
[0098] In some cases, methods for treating a mammal (e.g., a human) having one or more T cell disorders (e.g., a T cell cancer (e.g., a cancer containing one or more TRBC1+cancer cells), a T cell driven autoimmune disease (e.g., an autoimmune disease driven by one or more self-activated TRBC1+cells), and / or a T cell mediated rejection (e.g., a transplant rejection where a recipient's TRBC1+T cells are activated against a transplanted tissue)) provided herein can include administering to the mammal one or more binding agents (e.g., scFvs, antigen binding domains, and antibodies) provided herein (e.g., a binding agent that can target (e.g., target and bind) a TRBC1 polypeptide) as the sole active ingredient(s) to treat the mammal. For example, a composition containing one or more binding agentsAtorney Docket No. 44807-0516WO1 / P18787-02
[0099] provided herein can include the one or more binding agents as the sole active ingredient in the composition that is effective to treat a mammal having cancer.
[0100] In some cases, one or more binding agents (e.g., scFvs, antigen binding domains, and antibodies) provided herein (e.g., a binding agent that can target (e.g., target and bind) a TRBC1 polypeptide) can be administered to a mammal (e.g., a human) having one or more T cell disorders (e.g., a T cell cancer (e.g., a cancer containing one or more TRBC1+cancer cells), a T cell driven autoimmune disease (e.g., an autoimmune disease driven by one or more self-activated TRBC1+cells), and / or a T cell mediated rejection (e g., a transplant rejection where a recipient's TRBC1+T cells are activated against a transplanted tissue)) together with one or more (e.g., one, two, three, four, or more) additional agents / therapies used to treat a T cell disorder.
[0101] When one or more binding agents (e.g., scFvs, antigen binding domains, and antibodies) provided herein (e.g., a binding agent that can target (e.g., target and bind) a TRBC1 polypeptide) are administered to a mammal (e.g., a human) having a T cell cancer (e.g., a cancer containing one or more TRBC1+cancer cells) together with one or more (e.g., one, two, three, four, or more) additional agents / therapies used to treat a T cell cancer, any appropriate additional agents / therapies can be used. For example, one or more binding agents that can target (e.g., target and bind) a TRBC1 polypeptide (e.g., TRBC1+T cell receptor) can be administered to a mammal having a T cell cancer together with one or more (e.g., one, two, three, four, or more) anti-cancer agents. In some cases, an anti-cancer agent can be a chemotherapeutic agent. In some cases, an anti -cancer agent can be an immunotherapeutic agent. Examples of anti-cancer agents include, without limitation, trametinib, dabrafenib, binimetinib, selumntinib, vemurafenib, encorafenib, cobimetinib, busulfan, cisplatin, carboplatin, paclitaxel, docetaxel, nab-paclitaxel, altretamine, capecitabine, cyclophosphamide, etoposide (vp-16), gemcitabine, ifosfamide, irinotecan (cpt-11), liposomal doxorubicin, melphalan, pemetrexed, topotecan, vinorelbine, goserelin, leuprolide, tamoxifen, letrozole, anastrozole, exemestane, bevacizumab, olaparib, rucaparib, niraparib, and any combinations thereof. In cases where one or more binding agents provided herein are used with one or more additional agents treat a cancer, the one or more additional agents can be administered at the same time (e.g., in a single composition) or independently. In someAtorney Docket No. 44807-0516WO1 / P18787-02
[0102] cases, one or more binding agents provided herein can be administered first, and the one or more additional agents administered second, or vice versa.
[0103] In some cases, one or more binding agents (e.g., scFvs, antigen binding domains, and antibodies) provided herein (e.g., a binding agent that can target (e.g., target and bind) a TRBC1 polypeptide) can be administered to a mammal having a T cell cancer together with subjecting the mammal to one or more (e.g., one, two, three, four, or more) anti-cancer therapies. Examples of anti-cancer therapies include, without limitation, surgery, radiation therapy, carbon ion therapy, and proton therapy. Tn cases where one or more binding agents provided herein are used in combination with one or more additional therapies used to treat cancer, the one or more additional therapies can be performed at the same time or independently of the administration of one or more binding agents provided herein. For example, the one or more binding agents provided herein can be administered before, during, and / or after the one or more additional therapies are performed.
[0104] In certain instances, a T cell cancer (e.g., a cancer containing one or more TRBC1+cancer cells) within a mammal (e.g., a human) can be monitored to evaluate the effectiveness of a cancer treatment described herein. Any appropriate method can be used to determine whether or not a mammal having a T cell cancer is treated. For example, imaging techniques or laboratory assays can be used to assess the number of cancer cells and / or the size of a tumor present within a mammal. For example, imaging techniques or laboratory assays can be used to assess the location of cancer cells and / or a tumor present within a mammal.
[0105] When one or more binding agents (e.g., scFvs, antigen binding domains, and antibodies) provided herein (e.g., a binding agent that can target (e.g., target and bind) a TRBC1 polypeptide) are administered to a mammal (e.g., a human) having a T cell driven autoimmune disease (e.g., an autoimmune disease driven by one or more self-activated TRBC1+cells) together with one or more (e.g., one, two, three, four, or more) additional agents / therapies used to treat a T cell driven autoimmune disease, any appropriate additional agents / therapies can be used. In some cases, an agent that can be used to treat a T cell driven autoimmune disease can be a corticosteroid. In some cases, an agent that can be used to treat a T cell driven autoimmune disease can be an immunosuppressant. In some cases, an agent that can be used to treat a T cell driven autoimmune disease can be an anti-inflammatory. InAtorney Docket No. 44807-0516WO1 / P18787-02
[0106] some cases, an agent that can be used to treat a T cell driven autoimmune disease can be a non-steroidal anti-inflammatory drug (NSAID). Examples of agents that can be used to treat a T cell driven autoimmune disease include, without limitation prednisone, dexamethasone, azathioprine, methotrexate, aspirin, ibuprofen (e.g., ADVIL® and MOTRIN®), naproxen (e.g., ALEVE® and ANAPROX®), and any combinations thereof. In cases where one or more binding agents provided herein are used with one or more additional agents treat a T cell driven autoimmune disease, the one or more additional agents can be administered at the same time (e.g., in a single composition) or independently. In some cases, one or more binding agents provided herein can be administered first, and the one or more additional agents administered second, or vice versa.
[0107] In some cases, one or more binding agents (e.g., scFvs, antigen binding domains, and antibodies) provided herein (e.g., a binding agent that can target (e.g., target and bind) a TRBC1 polypeptide) can be administered to a mammal having a T cell driven autoimmune disease together with subjecting the mammal to one or more (e.g., one, two, three, four, or more) therapies for treating a T cell driven autoimmune disease. Examples of therapies for treating a T cell driven autoimmune disease include, without limitation, cellular therapies (e.g., CAR-T cell therapies targeting T cells). In cases where one or more binding agents provided herein are used in combination with one or more additional therapies used to treat a T cell driven autoimmune disease, the one or more additional therapies can be performed at the same time or independently of the administration of one or more binding agents provided herein. For example, the one or more binding agents provided herein can be administered before, during, and / or after the one or more additional therapies are performed.
[0108] In certain instances, a T cell driven autoimmune disease (e.g., an autoimmune disease driven by one or more self-activated TRBC1+cells) within a mammal (e.g., a human) can be monitored to evaluate the effectiveness of a T cell driven autoimmune disease treatment described herein. Any appropriate method can be used to determine whether or not a mammal having a T cell driven autoimmune disease is treated. For example, CT scans, PET scans, MRI scans, flow cytometry, biopsy, and / or immunohistochemistry can be used to assess the number of activated TRBC1+cells (e.g., self-activated TRBC1+cells) within a mammal.Atorney Docket No. 44807-0516WO1 / P18787-02
[0109] The invention will be further described in the following examples, which do not limit the scope of the invention described in the claims.
[0110] EXAMPLES
[0111] Example I: Generation ofTRBCl binding agents for T cell disorders
[0112] This Example describes the generation of binding agents that target (e.g., target and bind) to a TRBC1 polypeptide. TRBC1 polypeptides are present on the surface of T cells. Accordingly, these antibodies can be used for the detection and treatment of T cell disorders such as T cell cancers, T cell driven autoimmune disorders, and T cell mediated rejection.
[0113] Generation ofTRBCl binding agents
[0114] To develop an anti-TRBCl antibody with enhanced binding affinity for TRBC1 and minimal or no binding to TRBC2, the sequence of the YR3-A5 single-chain variable fragment (scFv), which binds to TRBC2, was modified. Each amino acid residue within the six complementarity-determining regions (CDRs) — comprising heavy chain CDRs (CDR-H1 to H3) and light chain CDRs (CDR-L1 to L3) — was systematically substituted with the remaining 19 canonical amino acids, resulting in the creation of 1,406 unique antibody variants. The CDRs in the YR3-A5 scFv were identified using the AbYsis tool, leading to the selection of 74 variant sites, including adjacent residues containing uncommon amino acids. A variant library containing these 1,406 modified sequences plus the original sequence was synthesized and cloned into the pADL-lOb phagemid vector. Next-generation sequencing validated the identity of this single variant library. The scFv sequences were expressed in phage, which were then propagated and applied to TRBC2+wild-type HPB-ALL cells and CRISPR-edited HPB-ALL cells expressing TRBC1+TCR (Figure 1).
[0115] To assess binding affinity, a sequencing-linked immunosorbent assay (SLISY) leveraging massively parallel sequencing (MPS) via an Illumina MiSeq system was employed. Since the -700 bp scFv sequences exceeded the MiSeq read length capacity, the Illumina standard software and methods were adapted to enable sequential amplification using specific primers. Sequencing data were indexed and analyzed using unique identifiers (UTDs), while truncated nucleotide sequences were translated into amino acids using PythonAtorney Docket No. 44807-0516WO1 / P18787-02
[0116] (version 3.7.17) within a JupyterLab notebook (version 1.2.6) via Anaconda3 Navigator (version 1.9.12).
[0117] For binding and enrichment analysis, sequences with one or no amino acid substitutions were analyzed. Read counts for each clone were used to generate a 95% confidence interval based on an approximated normal distribution. The upper and lower confidence bounds were calculated as the read count ± 2 times the square root of the read count. To ensure stringent selection, the upper bound was applied for TRBC2+cell reads, while the lower bound was used for TRBC1+cell reads.
[0118] Phage clones expressing scFvs were ranked based on their binding ratio (the proportion of phages binding to TRBC1+cells relative to TRBC2+cells) and their enrichment ratio (the proportion of a given clone binding to TRBC1+cells compared to its initial representation in the library) (Table 3). scFv-bearing phages exhibiting selective and high-affinity binding to TRBC1+cells showed both high binding and enrichment ratios.
[0119] Table 3.
[0120] Binding Enrichment ratio ratio
[0121] # phages on # phages on # phages on TRBCV fraction of fraction of fraction on TRBC1' TRBC2RTRBCt « phages on TRBC2' phage on TRSC2’ phage in library fraction tn library 4 / 6 4 / 12
[0122] 4712 2 / 6 3 / 12 ~1 3
[0123] 3 / 12 " * 0 / 6 5 / 12 5^(2
[0124]
[0125] Antibody production
[0126] Recombinant anti-TRBCl antibodies that incorporated the top scFv sequences were generated. The antibody sequences are shown in Example 2.
[0127] The antibody heavy and light chains were inserted into the pcDNA3.4 expression vector and expressed in ExpiCHO or CHO-S cells. Purification was carried out using either aAtorney Docket No. 44807-0516WO1 / P18787-02
[0128] HisTrap™ column or AmMag Protein A Magnetic Beads. Preparative size-exclusion chromatography was conducted using a HiLoad™ 26 / 600 Superdex 200pg column (320 mL) at a flow rate of 3.2 mL / min. For analytical size-exclusion chromatography, samples were first filtered through a 0.2 pm membrane before injecting approximately 20 pg of antibody into a TSKgel G3000SWxl column (7.8 mm x 300 mm, 5 pm particle size) with a TSKgel Guard Column SWxl (6.0 mm x 40 mm). The mobile phase consisted of 0.1 mol / L Na2SC>4 in 0.1 mol / L phosphate buffer (pH 6.7 ± 0.3), with a flow rate of 0.7 mL / min.
[0129] Binding to TRBC1 and TRBC2 peptides
[0130] Sensorgrams were recorded using a Biacore T200 (Cytiva) instrument at 25°C.
[0131] Protein A / G, initially prepared at a 50 pM stock concentration, was diluted 1 : 50 to a final concentration of 1 pM in 10 mM sodium acetate buffer (pH 4.5) and immobilized onto all flow cells (FCs) to approximately 2800 RU using standard amine coupling. Antibody clones were captured as ligands onto a CM5 chip, while TRBC1 (Aero Biosystems, TR1-H52H4) and TRBC2 (Aero Biosystems, TR2-H52H3) proteins served as analytes flowing over the ligand-bound surfaces. Overnight kinetic measurements were conducted for all analytes in a buffer containing 20 mM phosphate (pH 7.4), 137 mMNaCl, 2.7 mM KC1, and 0.05% (v / v) surfactant P20 (PBS-P). Analyte solutions were introduced at a flow rate of 50 pL / min, with contact and dissociation times set to 60 and 300 seconds, respectively. Surface regeneration was performed using two 20-second pulses of a 1:500 dilution of H3PO4 in deionized water.
[0132] Clone JOVL1 Clone 6R62Y Close 6K62Y
[0133] (FC:3-1) (EC:4-1)
[0134] Kn(nM) Kn(nM) KD(IIMJ
[0135] TRBC'1 4.1) 11.4 10.3
[0136] IRBC2 218.4 94.3 IXS.S
[0137]
[0138] CD3t.g Ml NB NB
[0139] Multiple-cycle kinetic experiments involved injecting threefold serial dilutions of analytes, ranging from 1000 nM to 4.1 nM. Sensorgrams were analyzed using the BiacoreAtorney Docket No. 44807-0516WO1 / P18787-02
[0140] T200 evaluation software (version 3.2.1) and fitted to a 1:1 kinetic binding model. The resulting sensorgrams are presented in Figure 2.
[0141] Binding to TRBC1+cells
[0142] T cells were obtained from a healthy human donor. Peripheral blood mononuclear cells (PBMCs) were isolated from leukapheresis products (Cellero, Stemcell Technologies) using Ficoll Paque Plus (GE Healthcare, GE17-1440-02) density gradient centrifugation. To expand and isolate human T cells, PBMCs were cultured with Human T-Activator CD3 / CD28 Dynabeads (Thermo Fisher Scientific, 1113 ID) at a bead-to-cell ratio of 1 : 1 for three days.
[0143] T cells were maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin, recombinant human IL-2 (100 lU / ml) (aldesleukin, Prometheus Therapeutics and Diagnostics), and recombinant human IL-7 (5 ng / ml) (BioLegend, 581906). Stained cells were analyzed using either an Attune NxT (Thermo Fisher) or an Attune CytPix (Thermo Fisher), with results presented in Figure 3.
[0144] ADC mediated killing of TRBC1+ cells
[0145] The ADC payload SG3249 (a pyrrolobenzodiazepine (PBD) dimer) was conjugated to the 6K62Y and 6R62Y anti-TRBCl antibodies. Dose-dependent cytotoxicity of the 6K62Y-SG3249 ADC and the 6R62Y-SG3249 ADC was observed in TRBC1+cancer cells (Fig. 4). A half-maximal inhibitory concentration (IC50) of 11.4 to 54.7 ng / mL was achieved with the 6K62Y-SG3249 ADC and the 6R62Y-SG3249 ADC.
[0146] Summary
[0147] Together these results demonstrate that the generated TRBC1 binding agents bind to a TRBC1 polypeptide and TRBC1+cells with high affinity, but demonstrate minimal binding to a TRBC2 polypeptide or TRBC2+cells.Atorney Docket No. 44807-0516WO1 / P18787-02
[0148] Example 2: Exemplary TRBC1 binding agents
[0149] This Example shows sequences of exemplary TRBC1 binding agents generated in Example 1. |Bold / highlighted| text indicates the CDR regions and unformatted text indicates
[0150]
[0151] the framework regions.
[0152] anti-TRBCl antibody clone 6R62Y
[0153] Antibody Light chain variable region (SEQ ID NO: 13)
[0154] Antibody heavy chain variable region (SEQ ID NO: 14) QVQLVQSGAEVKKPGASVKVSCKAS|PRGFHGYHMH|WVRQAPGQGLEWMG|FINPYNDDIQSNE RFRGRVTMTSDKSTTTAYMELSSLRSEDTAVYYCARGNGYWGDGAYRFFDFWGQGTLVTVSS
[0155] anti-TRBCl antibody clone 6K62Y
[0156] Antibody Light chain variable region (SEQ ID NO: 15)
[0157]
[0158] Antibody heavy chain variable region (SEQ ID NO: 16) QVQLVQSGAEVKKPGASVKVSCKAS|PRGFHGYHMH|WVRQAPGQGLEWMG|FINPYNDDIQSNE RFRGRVTMTSDKSTTTAYMELSSLRSEDTAVYYCARGNGYWGDGAYRFFDFWGQGTLVTVSS
[0159] Example 3: Treating a T cell cancer
[0160] A human identified as having a T cell cancer (e.g., a cancer containing one or more TRBC1+cancer cells) is administered a composition (e.g., a pharmaceutically acceptable composition) including:Atorney Docket No. 44807-0516WOI / P18787-02
[0161] (a) one or more antibodies including (i) a light chain having a VL CDR1 including the amino acid sequence set forth in SEQ ID NO: 1, a VL CDR2 including the amino acid sequence set forth in SEQ ID NO:2, and a VL CDR3 including the amino acid sequence set forth in SEQ ID NO:3 (e.g., a light chain including the amino acid sequence set forth in SEQ ID NO: 13), and / or (ii) a heavy chain having a VH CDR1 including the amino acid sequence set forth in SEQ ID NO:4, a Vn CDR2 including the amino acid sequence set forth in SEQ ID NO:5, and a VH CDR3 including the amino acid sequence set forth in SEQ ID NO:6 (e.g., a heavy chain including the amino acid sequence set forth in SEQ ID NO: 14); and / or (b) one or more antibodies including one or more antibodies including (i) a light chain having a VL CDR1 including the amino acid sequence set forth in SEQ ID NO: 7, a VL CDR2 including the amino acid sequence set forth in SEQ ID NO: 8, and a VL CDR3 including the amino acid sequence set forth in SEQ ID NOV (e.g., a light chain including the amino acid sequence set forth in SEQ ID NO: 15), and / or (ii) a heavy chain having a VH CDR1 including the amino acid sequence set forth in SEQ ID NO: 10, a VH CDR2 including the amino acid sequence set forth in SEQ ID NO: 11, and a VH CDR3 including the amino acid sequence set forth in SEQ ID NO: 12 (e.g., a heavy chain including the amino acid sequence set forth in SEQ ID NO: 16).
[0162] The administered antibodies(s) can reduce or eliminate the number of TRBC1+cancer cells within the human.
[0163] Example 4: Treating a T cell driven autoimmune disease
[0164] A human identified as having a T cell driven autoimmune disease (e.g., an autoimmune disease driven by one or more self-activated TRBC1+cells) is administered a composition (e.g., a pharmaceutically acceptable composition) including:
[0165] (a) one or more antibodies including (i) a light chain having a VL CDR1 including the amino acid sequence set forth in SEQ ID NO: 1, a Vi. CDR2 including the amino acid sequence set forth in SEQ ID NO:2, and a VL CDR3 including the amino acid sequence set forth in SEQ ID NO:3 (e.g., a light chain including the amino acid sequence set forth in SEQ ID NO: 13), and / or (ii) a heavy chain having a VH CDR1 including the amino acid sequence set forth in SEQ ID NO:4, a VH CDR2 including the amino acid sequence set forth in SEQAttorney Docket No. 44807-0516WOI / P18787-02
[0166] ID N0:5, and a VH CDR3 including the amino acid sequence set forth in SEQ ID NO:6 (e.g., a heavy chain including the amino acid sequence set forth in SEQ ID NO: 14); and / or (b) one or more antibodies including one or more antibodies including (i) a light chain having a VL CDR1 including the amino acid sequence set forth in SEQ ID NO: 7, a VL CDR2 including the amino acid sequence set forth in SEQ ID NO: 8, and a VL CDR3 including the amino acid sequence set forth in SEQ ID NO: 9 (e.g., a light chain including the amino acid sequence set forth in SEQ ID NO: 15), and / or (ii) a heavy chain having a VH CDR1 including the amino acid sequence set forth in SEQ ID NO: 10, a VH CDR2 including the amino acid sequence set forth in SEQ ID NO: 11, and a VH CDR3 including the amino acid sequence set forth in SEQ ID NO: 12 (e.g., a heavy chain including the amino acid sequence set forth in SEQ ID NO: 16).
[0167] The administered antibodies(s) can reduce or eliminate the number of self-activated TRBC1+cancer cells within the human.
[0168] OTHER EMBODIMENTS
[0169] It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.
Claims
Attorney Docket No. 44807-0516WO1 / P18787-02WHAT IS CLAIMED IS:
1. A binding agent that can bind to a T cell receptor (TCR) P chain constant region 1 (TRBC1) polypeptide, wherein said binding agent comprises:(i) a light chain variable domain comprising: a VL CDR1 that comprises or consists essentially of the amino acid sequences set forth in SEQ ID NO:1, a VL CDR2 that comprises or consists essentially of the amino acid sequences set forth in SEQ ID NO:2, and a VL CDR3 that comprises or consists essentially of the amino acid sequences set forth in SEQ ID NO:3; or(ii) a heavy chain variable domain comprising: a VH CDR1 that comprises or consists essentially of the amino acid sequences set forth in SEQ ID NO:4, a VH CDR2 that comprises or consists essentially of the amino acid sequences set forth in SEQ ID NO:5, and a VH CDR3 that comprises or consists essentially of the amino acid sequences set forth in SEQ IDNO:6.
2. The binding agent of claim 1, wherein said binding agent comprises said light chain variable domain of said (i).
3. The binding agent of claim 2, wherein said light chain variable domain comprises an amino acid sequence having at least 90 percent identity to the amino acid sequence set forth in SEQ ID NO: 13.
4. The binding agent of claim 1, wherein said binding agent comprises said heavy chain variable domain of said (ii).
5. The binding agent of claim 4, wherein said heavy chain variable domain comprises an amino acid sequence having at least 90 percent identity to the amino acid sequence set forth in SEQ ID NO: 14.Attorney Docket No. 44807-0516WO1 / P18787-026. The binding agent of claim 1, wherein said binding agent comprises said light chain variable domain of said (i) and comprises said heavy chain variable domain of said (ii).
7. A binding agent that can bind to a TRBC1 polypeptide, wherein said binding agent comprises:(i) a light chain variable domain comprising: a VL CDR1 that comprises or consists essentially of the amino acid sequences set forth in SEQ ID NO:7, a VL CDR2 that comprises or consists essentially of the amino acid sequences set forth in SEQ ID NO:8, and a VL CDR3 that comprises or consists essentially of the amino acid sequences set forth in SEQ ID NO:9; or(ii) a heavy chain variable domain comprising: a VH CDR1 that comprises or consists essentially of the amino acid sequences set forth in SEQ ID NO: 10, a VH CDR2 that comprises or consists essentially of the amino acid sequences set forth in SEQ ID NO: 11, and a VH CDR3 that comprises or consists essentially of the amino acid sequences set forth in SEQ ID NO: 12.
8. The binding agent of claim 7, wherein said binding agent comprises said light chain variable domain of said (i).
9. The binding agent of claim 8, wherein said light chain variable domain comprises an amino acid sequence having at least 90 percent identity to the amino acid sequence set forth in SEQ ID NO: 15.
10. The binding agent of claim 7, wherein said binding agent comprises said heavy chain variable domain of said (ii).
11. The binding agent of claim 10, wherein said heavy chain variable domain comprises an amino acid sequence having at least 90 percent identity to the amino acid sequence set forth in SEQ ID NO: 16.Attorney Docket No. 44807-0516WO1 / P18787-0212. The binding agent of claim 7, wherein said binding agent comprises said light chain variable domain of said (i) and comprises said heavy chain variable domain of said (ii).
13. The binding agent of any one of claims 1-12, wherein said binding agent is selected from the group consisting of a single chain variable fragment (scFv), an antigen binding domain, and an antibody.
14. The binding agent of any one of claims 1-13, wherein said binding agent is a monoclonal antibody.
15. A nucleic acid encoding the binding agent of any one of claims 1-14.
16. The nucleic acid of claim 15, wherein said nucleic acid is in the form of a vector.
17. The nucleic acid of claim 16, wherein said vector is an expression vector.
18. The nucleic acid of claim 16, wherein said vector is a viral vector.
19. An antibody-drug conjugate (ADC) comprising a binding agent of any one of claims 1-14 covalently linked to a drug.
20. The ADC of claim 19, wherein said drug is selected from the group consisting of monomethyl auristatin E (MMAE), monomethyl auristatin F (MMAF), mertansine (DM-1), pyrrolobenzodiazepine (PBD) dimers, DM4, A-Acetyl-calicheamicin, duocarmycin, DXd, and SN38.
21. A method for treating a mammal having a T cell cancer, said method comprising administering to said mammal the binding agent of any one of claims 1-14, the nucleic acid of any one of claims 15-18, or the ADC of any one of claims 19-20, wherein said T cell cancer comprises a cancer cell expressing a TRBC1 polypeptide.Attorney Docket No. 44807-0516WO1 / P18787-0222. The method of claim 19, wherein said T cell cancer is selected from the group consisting of acute lymphoblastic leukemia (ALL), peripheral T cell lymphomas (PTCL), angioimmunoblastic T cell lymphomas (AITL), T cell prolymphocytic leukemia (T-PLL), adult T cell leukemia / lymphoma (ATLL), Enteropathy-associated T-cell lymphoma (EATL), monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL), follicular T-cell lymphoma (FTCL), nodal peripheral T-cell lymphoma (nodal PTCL), cutaneous T cell lymphomas (CTCL), anaplastic large cell lymphoma (ALCL), T-cell large granular lymphocytic leukemia (T-LGL), extra nodal NK / T-Cell lymphoma (NKTL), and hepatosplenic T-cell lymphoma.
23. The method of any one of claims 21-22, wherein said method is effective to reduce or eliminate a number of TR.BC I cancer cells within said mammal.
24. The method of any one of claims 21-23, wherein said mammal is a human.
25. A method for treating a mammal having a T cell driven autoimmune disease, said method comprising administering to said mammal the binding agent of any one of claims 1-14, the nucleic acid of any one of claims 15-18, or the ADC of any one of claims 19-20, wherein said T cell driven autoimmune disease comprises a self-activated T cell expressing a TRBC1 polypeptide.
26. The method of claim 25, wherein said T cell driven autoimmune disease is selected from the group consisting of multiple sclerosis (MS), Type 1 diabetes, rheumatoid arthritis, systemic lupus erythematosus (SLE), psoriasis, psoriatic arthritis, ankylosing spondylitis, celiac disease, vitiligo, and Bechet’s disease.
27. The method of any one of claims 25-26, wherein said method is effective to reduce or eliminate a number of self-activated TRBCL cells within said mammal.Attorney Docket No. 44807-0516WO1 / P18787-0228. The method of any one of claims 25-27, wherein said mammal is a human.
29. A method for treating a mammal experiencing T cell mediated rejection, said method comprising administering to said mammal the binding agent of any one of claims 1-14, the nucleic acid of any one of claims 15-18, or the ADC of any one of claims 19-20, wherein said T cell mediated rejection comprises an activated T cell expressing a TRBC1 polypeptide.
30. The method of claim 29, wherein said T cell mediated rejection comprises rejection of an organ transplant or a bone marrow transplant.
31. The method of any one of claims 29-30, wherein said method is effective to reduce or eliminate a number of activated TRBC1-cells within said mammal.
32. The method of any one of claims 29-31, wherein said mammal is a human.
33. The use of a composition comprising the binding agent of any one of claims 1-14, the nucleic acid of any one of claims 15-18, or the ADC of any one of claims 19-20 to treat a T cell disorder.
34. The binding agent of any one of claims 1-14, the nucleic acid of any one of claims 15-18, or the ADC of any one of claims 19-20 for use in the preparation of a medicament to treat a T cell disorder.
35. The binding agent of any one of claims 1-14, the nucleic acid of any one of claims 15-18, or the ADC of any one of claims 19-20 for use in the treatment of a T cell disorder.
